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Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly
used drugs, but much attention has been focused on the relationship
of these drugs to cardiovascular conditions.1 In this issue of European
Heart Journal – Cardiovascular Pharmacotherapy,Olsen et al.2 reported
on an association, which has had perhaps less attention: the higher
riskof developing atrial fibrillation (AF) in patientswith priormyocar-
dial infarction (MI) taking NSAIDs. The authors reported a
crude event incidence of 2.2 [95% confidence interval (CI) 2.0–
2.4] per 100 person-years in post-MI patients prescribed with
NSAIDs, compared with patients never prescribed. The adjusted
multivariable risk analysis showed that NSAIDs were associated
with a hazard ratio (HR) equal to 1.27 (95% CI 1.14–1.40). The
risk of developing AF remains high regardless of NSAID type and
length of treatment. Olsen et al. provide a detailed analysis of con-
founding factors, demonstrating that co-morbidities like rheumatic
disease, possibly influencing the NSAID prescription, did not affect
AF onset and risk.
Nonetheless, AF is frequently reported in the post-MI clinical
scenario,3 complicating the rehabilitation process and heavily influ-
encing patients’ clinical and pharmacological management, with
an increased risk of heart failure, as well as stroke and thrombo-
embolism.4 Based on the CHA2DS2-VASc score,
5 AF patients
with previous vascular disease (i.e. previous MI, aortic disease,
and peripheral arterial disease) gain at least one added point in
their thromboembolic risk assessment.
Clearly, if a MI patient develops AF, such patients would be at high
stroke risk, and anticoagulant therapy is recommended for stroke
prevention.6,7 Effective stroke prevention means oral anticoagulant
(OAC) therapy, whether with a vitamin K antagonist [VKA, but
with good quality anticoagulation control, with a high time in a thera-
peutic range (.70%) to maximize efficacy and safety8,9] and more
recently, with the non-VKAOACs (NOACs, previously referred to
as new or novel OACs10). However, if NSAIDs are also used, the
risk of serious bleeding is substantially increased.11,12
Is the association between AF and NSAIDs relevant? These data
from Olsen et al. are of particular interest, and are consistent with
previous reports,13,14 indicating an higher risk of developing AF in
patients undertaking treatment with NSAIDs, in the particular
setting of patients with previous MI. AF is more prevalent in the
elderly, and osteoarthritis and other joint conditions are common
in the elderly, leading to more common NSAID use, even out with
their indications and regardless of possible side effects.15
What can explain the higher risk of developing AF in post-MI
patients treated with NSAIDs? The latter drugs are related to co-
morbidities such as hypertension, heart failure, or even kidney
disease. These clinical conditions are also common in AF patients
and strongly influence the complications related to AF, such as
stroke. However, the precise mechanistic pathways linking AF and
NSAIDs are only speculative. For now, greater awareness of the inher-
ent cardiovascular risks of NSAIDs is needed, including the risk of
developing AF and its complications, as well as the potential serious
harms from concomitant use of drug treatments, such as OAC in AF.
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